CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Codexis and Merck Renew Supply Agreement for Sitagliptin Enzyme

Life Sciences Review Life Sciences Review | Tuesday, September 21, 2021
Tweet

Codexis and Merck renew supply agreement for the enzyme used in the Sitagliptin manufacturing process.


FREMONT, CA: Codexis, Inc., a leader in enzyme engineering that enables the promise of synthetic biology, has extended its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient (API) in Merck's JANUVIA® and one of the atypical antipsychotic medications.


“Codexis relationship with Merck spans more than a decade, including R&D collaboration, a CodeEvolver® license, and commercial product supply, and we are proud to extend our partnership even further for the supply of this proprietary, high-performance enzyme for the API in JANUVIA®,” says John Nicols, President, and CEO of Codexis. “Our CodeEvolver® enzyme engineering platform enables Codexis and our partners to design unique enzymes with performance improvements that dramatically reduce the cost and improve the efficiency and sustainability of their API manufacturing.”


Codexis and Merck have collaborated on a research and development agreement to develop a novel, proprietary enzyme to act as a biocatalyst in the sitagliptin manufacturing process. The resulting enzyme simplified the manufacturing process and enhanced output while lowering costs and waste. In 2010, the US Environmental Protection Agency (EPA) awarded Codexis and Merck the annual Presidential Green Chemistry Challenge Award for developing this unique biocatalytic technique for sitagliptin production. Codexis and Merck inked a supply deal for the enzyme in 2012 and a multi-year extension in 2015, both of which were set to expire in February 2022. The following extension and amendment cover the licensing and delivery of the proprietary enzyme through December 31, 2026. The extension may be renewed for a further five years if both firms agree.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/codexis-and-merck-renew-supply-agreement-for-sitagliptin-enzyme-nwid-564.html